Please login to the form below

Not currently logged in
Email:
Password:

PhRMA names advocacy chief

Pharmaceutical Research and Manufacturers of America has named AZ's Chip Davis to serve as executive vice president of advocacy

Pharmaceutical Research and Manufacturers of America (PhRMA) has named AstraZeneca's (AZ) Chip Davis to serve as executive vice president of advocacy, a newly created position, effective immediately.

Davis has been on a leave of absence from his post as vice president of corporate External Relations at AZ since mid-April, when he joined PhRMA to serve as senior operating officer, providing day-to-day leadership at the trade organisation following the departure of the trade group's CEO, Billy Tauzin. He also played a key role in the search for Tauzin's replacement, a process that was led by AZ CEO David Brennan.

In his permanent position at PhRMA, he will be responsible for leading the organisation's federal, state and international government relations and advocacy efforts.

Before his leave of absence from AZ, Davis was the company's official liaison to PhRMA, a responsibility he took on beginning in 2004.  He was also responsible for overseeing the pharma firm's government relations and reimbursement teams, as well as strategic alliances and community relations.

After Davis took on the role of senior operating officer at PhRMA, there was speculation in the trade press and in Internet communities that he would eventually be named the organisation's CEO. However, that role in the end went to John Castellani, formerly president of the Business Roundtable, and Davis stayed on to help manage the transition. In his new role, Davis reports directly to Castellani.

Davis holds an undergraduate degree in accounting from the University of Delaware and a law degree from the University of Baltimore. He is a member of the bar in the District of Columbia, Maryland and Virginia.

15th November 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics